Search

Memorial Sloan Kettering social worker Melissa Stewart has been awarded the Assocation of Oncology Social Work (AOSW)’s Dennis Roth Neuro-Oncology Social Worker of the Year for 2010. She will be honored at the AOSW conference in Phoenix, Arizona on May 2, 2010.

The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published in The New England Journal of Medicine and presented at the 49th Annual Meeting of the American Society of Clinical Oncology.

New MSK research finds a way to package protein-degrading drugs called PROTACs into nanoparticles that target blood vessels within solid tumors; identifies genomic markers that predict whether precancerous blood conditions will turn into multiple myeloma; develops a data-driven approach that could catch lymphedema earlier; and shows that nurse-led palliative care delivered by phone could serve as a scalable model.

Thanks to a second opinion and minimally invasive surgery at MSK to remove tongue cancer, Karren Tyler is back home in Charlottesville, Virginia, cancer free and focused on giving back to other cancer patients.

After developing a noninvasive nanosensor to detect the progression of fatty liver disease in mice, researchers at the Sloan Kettering Institute have determined that there is a long-term effect on liver macrophages from eating a high-fat and high-sugar diet, even after switching back to a normal diet.

Learn about dense breast tissue and what it means for your cancer risk and screening needs.

Learn how a heralded clinical trial for rectal cancer led to Dr. Andrea Cercek of MSK meeting the 4-day-old newborn of her patient, who feared she could not get pregnant.

A newly published study demonstrates that imaging with Positron Emission Tomography (PET) using a radiolabeled antibody accurately identifies whether a patient has clear cell renal carcinoma - the most common and aggressive type of renal tumor - and arms the urologist with crucial information that will help determine whether surgery is needed.